Howard West

12.2k total citations · 7 hit papers
190 papers, 8.6k citations indexed

About

Howard West is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Howard West has authored 190 papers receiving a total of 8.6k indexed citations (citations by other indexed papers that have themselves been cited), including 134 papers in Pulmonary and Respiratory Medicine, 112 papers in Oncology and 31 papers in Cancer Research. Recurrent topics in Howard West's work include Lung Cancer Treatments and Mutations (123 papers), Lung Cancer Research Studies (53 papers) and Lung Cancer Diagnosis and Treatment (47 papers). Howard West is often cited by papers focused on Lung Cancer Treatments and Mutations (123 papers), Lung Cancer Research Studies (53 papers) and Lung Cancer Diagnosis and Treatment (47 papers). Howard West collaborates with scholars based in United States, Italy and Germany. Howard West's co-authors include Bradley T. Hyman, John H. Growdon, Teresa Gómez‐Isla, David R. Gandara, Stina Mui, Joseph E. Parisi, Ronald C. Petersen, Richard Hollister, G. William Rebeck and Paul H. Gumerlock and has published in prestigious journals such as Proceedings of the National Academy of Sciences, JAMA and Journal of Clinical Oncology.

In The Last Decade

Howard West

185 papers receiving 8.4k citations

Hit Papers

Neuronal loss correlates with but exceeds neurofibrillary... 1997 2026 2006 2016 1997 2019 2014 2015 2017 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease
    1997 1.1k citations Howard West et al. profile →
  2. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
    2019 1.1k citations Howard West, Michael McCleod et al. The Lancet Oncology profile →
  3. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study
    2014 538 citations Shirish M. Gadgeel, Leena Gandhi et al. The Lancet Oncology profile →
  4. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
    2015 462 citations Alice T. Shaw, Leena Gandhi et al. The Lancet Oncology profile →
  5. Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial
    2017 430 citations Karen L. Reckamp, Howard West et al. profile →
  6. Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial
    2020 290 citations Makoto Nishio, Fabrice Barlési et al. Journal of Thoracic Oncology profile →
  7. Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non–Small Cell Lung Cancer
    2023 102 citations Mark A. Socinski, Robert M. Jotte et al. JAMA Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Howard West United States 35 4.9k 4.8k 2.0k 1.6k 1.0k 190 8.6k
Masayuki Takeda Japan 55 3.2k 0.6× 3.3k 0.7× 2.4k 1.2× 855 0.5× 875 0.8× 436 10.9k
Joel B. Nelson United States 49 6.0k 1.2× 3.0k 0.6× 3.5k 1.8× 1.1k 0.6× 1.8k 1.7× 188 10.8k
William J.M. Hrushesky United States 46 839 0.2× 2.1k 0.4× 1.4k 0.7× 1.1k 0.7× 874 0.8× 193 6.7k
Judith R. OʼFallon United States 58 3.3k 0.7× 2.2k 0.5× 2.0k 1.0× 353 0.2× 1.5k 1.4× 125 11.2k
Toru Iwama Japan 46 1.8k 0.4× 886 0.2× 1.7k 0.8× 394 0.2× 786 0.8× 336 7.8k
Keith D. Wilner United States 45 7.4k 1.5× 6.2k 1.3× 3.2k 1.6× 140 0.1× 1.8k 1.7× 163 11.4k
Willem Boogerd Netherlands 54 6.8k 1.4× 3.2k 0.7× 861 0.4× 223 0.1× 451 0.4× 135 9.7k
José Trigo Spain 38 1.6k 0.3× 2.6k 0.5× 1.6k 0.8× 295 0.2× 470 0.5× 165 5.8k
Charles J. Vecht Netherlands 46 3.6k 0.7× 1.7k 0.4× 1.5k 0.8× 259 0.2× 851 0.8× 105 10.3k
Athanassios P. Kyritsis United States 48 1.5k 0.3× 2.0k 0.4× 3.2k 1.6× 210 0.1× 1.1k 1.1× 173 7.9k

Countries citing papers authored by Howard West

Since Specialization
Citations

This map shows the geographic impact of Howard West's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Howard West with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Howard West more than expected).

Fields of papers citing papers by Howard West

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Howard West. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Howard West. The network helps show where Howard West may publish in the future.

Co-authorship network of co-authors of Howard West

This figure shows the co-authorship network connecting the top 25 collaborators of Howard West. A scholar is included among the top collaborators of Howard West based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Howard West. Howard West is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sridhar, Arthi, Howard West, & Eric K. Singhi. (2024). Brief Report on Global Clinician Practices in the First-Line Management of Metastatic Non-Small Cell Lung Cancer. Clinical Lung Cancer. 25(7). e286–e294.
2.
3.
Barzi, Afsaneh, Howard West, David T. Wong, et al.. (2023). Pancreatic Adenocarcinoma: Real World Evidence of Care Delivery in AccessHope Data. Journal of Personalized Medicine. 13(9). 1377–1377. 1 indexed citations
4.
Turgeman, Ilit & Howard West. (2023). Adolescents and Young Adults With Cancer. JAMA Oncology. 9(3). 440–440. 14 indexed citations
5.
Uprety, Dipesh & Howard West. (2023). Malignant Pericardial Effusion, or Fluid Around the Heart Due to Cancer. JAMA Oncology. 10(1). 148–148. 1 indexed citations
6.
West, Howard, Erin M. Bange, & Fumiko Chino. (2023). Telemedicine as patient-centred oncology care: will we embrace or resist disruption?. Nature Reviews Clinical Oncology. 20(10). 659–660. 4 indexed citations
7.
Morgan, Gilberto, Neeraj Agarwal, Toni K. Choueiri, et al.. (2022). The (R)evolution of Social Media in Oncology: Engage, Enlighten, and Encourage. Cancer Discovery. 12(7). 1620–1624. 11 indexed citations
8.
Nishio, Makoto, Fabrice Barlési, Howard West, et al.. (2020). Atezolizumab Plus Chemotherapy for First-Line Treatment of Non-Squamous Non-Small Cell Lung Cancer: Results From the Randomized Phase III IMpower132 Trial.. Journal of Thoracic Oncology. 7 indexed citations
9.
West, Howard, Michael McCleod, Maen Hussein, et al.. (2019). Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. The Lancet Oncology. 20(7). 924–937. 1137 indexed citations breakdown →
10.
Spigel, David R., Robert M. Jotte, Santiago Ponce Aix, et al.. (2018). nab-paclitaxel + carboplatin induction followed by nab-paclitaxel maintenance in squamous non-small cell lung cancer (NSCLC): Results from the ABOUND.sqm study. Annals of Oncology. 29. viii749–viii750. 1 indexed citations
11.
Yu, Helena A., Alexander I. Spira, Leora Horn, et al.. (2017). A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non–small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations. Clinical Cancer Research. 23(24). 7467–7473. 23 indexed citations
12.
Camidge, D. Ross, Shirish M. Gadgeel, Leena Gandhi, et al.. (2017). MA07.02 Updated Efficacy and Safety Data from the Phase 2 NP28761 Study of Alectinib in ALK-Positive Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology. 12(1). S378–S378. 10 indexed citations
13.
Gaspar, Laurie E., et al.. (2017). OA16.02 Shared Decision Making (SDM) and Patient Decision Aids (PDAs) in Lung Cancer: Survey of Patients, Significant Others or Caregivers. Journal of Thoracic Oncology. 12(1). S304–S305. 1 indexed citations
14.
Wilshire, Candice L., Brian E. Louie, Ralph W. Aye, et al.. (2016). Comparison of outcomes for patients with lepidic pulmonary adenocarcinoma defined by 2 staging systems: A North American experience. Journal of Thoracic and Cardiovascular Surgery. 151(6). 1561–1568. 9 indexed citations
15.
Patel, Sandip Pravin, Nathan A. Pennell, Suchita Pakkala, et al.. (2016). Phase 1b study of crizotinib in combination with pembrolizumab in patients (pts) with untreated ALK-positive (+) advanced non-small cell lung cancer (NSCLC). Annals of Oncology. 27. vi449–vi449. 2 indexed citations
16.
17.
West, Howard, Rogério Lilenbaum, David H. Harpole, Antoinette J. Wozniak, & Lecia V. Sequist. (2009). Molecular Analysis-Based Treatment Strategies for the Management of Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 4(9). S1029–S1039. 30 indexed citations
18.
Hirsch, Fred R., Marileila Varella‐Garcia, Federico Cappuzzo, et al.. (2007). Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Annals of Oncology. 18(4). 752–760. 231 indexed citations
19.
Nemunaitis, John, Neil Senzer, Casey Cunningham, et al.. (2006). Phase I Trial of Sequential Administration of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small-Cell Lung Cancer. Molecular Therapy. 13(6). 1185–1191. 53 indexed citations
20.
West, Howard & Kathy S. Albain. (2005). Current Standards and Ongoing Controversies in the Management of Locally Advanced Non-Small Cell Lung Cancer. Seminars in Oncology. 32(3). 284–292. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Masayuki Takeda Breakdown of academic impact, for papers by Joel B. Nelson Breakdown of academic impact, for papers by William J.M. Hrushesky Breakdown of academic impact, for papers by Judith R. OʼFallon Breakdown of academic impact, for papers by Toru Iwama Breakdown of academic impact, for papers by Keith D. Wilner Breakdown of academic impact, for papers by Willem Boogerd Breakdown of academic impact, for papers by José Trigo Breakdown of academic impact, for papers by Charles J. Vecht Breakdown of academic impact, for papers by Athanassios P. Kyritsis
Rankless by CCL
2026